ESMO 2017 Congress

Oncology Meeting Resources

08 Sep - 12 Sep 2017, Madrid, Spain

ESMO-2017-square

The ESMO 2017 Congress, in partnership with the European Association for Cancer Research (EACR), will bring cancer researchers and clinicians together to enable collaboration and the exchange of ideas, from the laboratory to the bedside and back.
Presentations (slides) and webcasts are available to ESMO members according to the presenters' agreement to release them. Abstracts are open access. Congress attendees should access via the ESMO Conferences platform.
The use of these presentations is for personal educational purposes only. ESMO thanks the authors for their generosity. Meeting programme |Future ESMO meetings

Watch the ESMO scientific videos!

Special Sessions and Tracks





Format available

http://oncologypro.esmo.org/Meeting-Resources/ESMO-2017-Congress/EACR-Presidential-Address

Date: 08 Sep 2017
Presenter: Anton Berns
Resources: Webcast

http://oncologypro.esmo.org/Meeting-Resources/ESMO-2017-Congress/Welcome-to-Madrid

Date: 08 Sep 2017
Presenter: Miguel Martin Jimenez
Resources: Webcast

http://oncologypro.esmo.org/Meeting-Resourc...O-2017-Congress/ESMO-2017-Scientific-Address

Date: 08 Sep 2017
Presenter: Alberto Sobrero
Resources: Webcast

http://oncologypro.esmo.org/Meeting-Resourc...7-Congress/Presentation-of-the-ESMO-Award-by

Date: 08 Sep 2017
Presenter: Christoph Zielinski
Resources: Webcast

http://oncologypro.esmo.org/Meeting-Resourc...ng-and-targeting-colorectal-cancer-evolution

Date: 08 Sep 2017
Presenter: Alberto Bardelli

http://oncologypro.esmo.org/Meeting-Resourc...on-of-the-ESMO-Lifetime-Achievement-Award-by

Date: 08 Sep 2017
Presenter: Christoph Zielinski
Resources: Presentation, Webcast

http://oncologypro.esmo.org/Meeting-Resourc...ress/ESMO-Lifetime-Achievement-Award-lecture

Date: 08 Sep 2017
Presenter: José Baselga
Resources: Presentation, Webcast

http://oncologypro.esmo.org/Meeting-Resourc...radiotherapy-RT-a-randomized-phase-III-trial

BackgroundHrPC pts with PSA relapse after local therapy may have a poor prognosis and AS may be a therapeutic option. D+AS is standard of care in hormone-naive metastatic PC.

Date: 08 Sep 2017
Presenter: Stephane Oudard
Resources: Abstract, Presentation, Webcast
Topics: Anti-Cancer Agents & Biologic Therapy, Prostate Cancer, Genitourinary Cancers, Surgery and/or Radiotherapy of Cancer

http://oncologypro.esmo.org/Meeting-Resourc...esistant-prostate-cancer-treated-with-LuPSMA

BackgroundProgressive metastatic castrate-resistant prostate carcinoma (mCRPC) is a highly lethal condition. Lutetium-177 (177Lu)-PSMA617, a radiolabelled small molecule, binds with high affinity to...

Date: 08 Sep 2017
Presenter: Michael Hofman
Resources: Abstract, Presentation, Webcast
Topics: Prostate Cancer, Genitourinary Cancers

http://oncologypro.esmo.org/Meeting-Resourc...7-Congress/When-to-discontinue-immunotherapy

Date: 08 Sep 2017
Presenter: Caroline Robert
Resources: Presentation, Webcast
Topic: Cancer Immunology and Immunotherapy